coin-img-BTCBTC-0.57%coin-img-ETHETH-0.86%coin-img-SOLSOL-2.51%coin-img-XRPXRP-2.69%coin-img-USDCUSDC+0.00%coin-img-HYPEHYPE-2.56%coin-img-TRXTRX+0.27%coin-img-LABLAB-75.85%coin-img-BTCBTC-0.57%coin-img-ETHETH-0.86%coin-img-SOLSOL-2.51%coin-img-XRPXRP-2.69%coin-img-USDCUSDC+0.00%coin-img-HYPEHYPE-2.56%coin-img-TRXTRX+0.27%coin-img-LABLAB-75.85%coin-img-BTCBTC-0.57%coin-img-ETHETH-0.86%coin-img-SOLSOL-2.51%coin-img-XRPXRP-2.69%coin-img-USDCUSDC+0.00%coin-img-HYPEHYPE-2.56%coin-img-TRXTRX+0.27%coin-img-LABLAB-75.85%coin-img-BTCBTC-0.57%coin-img-ETHETH-0.86%coin-img-SOLSOL-2.51%coin-img-XRPXRP-2.69%coin-img-USDCUSDC+0.00%coin-img-HYPEHYPE-2.56%coin-img-TRXTRX+0.27%coin-img-LABLAB-75.85%
user-avatar
Moneycontrol

Orchid Pharma signs exclusive Russia licensing and supply deal for Exblifep, sees $178 million over 10 years

AI Market Summary
Orchid Pharma signed an exclusive licensing and supply pact with Russia's Pharmasyntez to register and commercialize Exblifep, with Orchid manufacturing finished doses. The drug is already FDA and EMA approved, and management cited a potential ~$178m revenue opportunity over 10 years contingent on Russian regulatory approval and hospital procurement dynamics. The news is idiosyncratic to a single equity and has limited broader cross-asset impact.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT-0.33%
AI Insight · NCCOGOLD2USD/USDTAI Insight
● Neutral
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Orchid Pharma has signed an exclusive licensing and supply agreement with Russia’s Pharmasyntez JSC for Exblifep (cefepime/enmetazobactam) in Russia, with Pharmasyntez handling registration and commercialization while Orchid manufactures the finished dosage form. The antibiotic has received approvals from the US Food and Drug Administration and the European Medicines Agency for treating complicated urinary tract infections and hospital-acquired pneumonia. The company said the partnership could generate about $178 million in revenue over the first 10 years. SUS is Orchid Pharma’s standard trading code in India.
Disclaimer: The content above is only the author's opinion and does not represent BingX’s stance. It shall not be construed as investment advice from BingX. For details, refer to the Terms and Conditions.
Stocks

Risk Warning

Cryptocurrencies and their derivatives are innovative financial products with great volatility and high investment risks.

Although BingX is committed to providing users with easy-to-use trading tools, trading itself is still a highly sophisticated field. Trading digital assets and their derivatives are subject to high market risk and price volatility and may result in partial or total loss of account funds. You must carefully consider and exercise clear judgment to evaluate your financial situation and the aforementioned risks before using BingX Services. You shall be responsible for all losses arising therefrom. If necessary, please consult relevant professionals to make informed decisions before investing. By accessing, downloading, using or clicking on "I agree" to accept any BingX Services provided by BingX, you agree that you have read, understood and accepted all of the terms and conditions stipulated in BingX Terms of Use as well as our Privacy Policy.


Trading by copying or replicating the trades of other traders involves a high level of risks, even when copying or replicating the top-performing traders. Past performance of a BingX community member is not a reliable indicator of his future performance. Content on BingX's trading platform is generated by members of its community and does not contain advice or recommendations by or on behalf of BingX.